Details for New Drug Application (NDA): 205529

NDA 205529 describes OXALIPLATIN, which is a drug marketed by Accord Hlthcare, Actavis, Actavis Totowa, Am Regent, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Oncol, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hengrui Pharma, Hospira Inc, Hospira Worldwide, Meitheal, Mylan Labs Ltd, Norvium Bioscience, Novast Labs, Qilu Pharm Hainan, Sandoz, Sun Pharm, and Teva Pharms, and is included in twenty-seven NDAs. It is available from eighteen suppliers. Additional details are available on the OXALIPLATIN profile page.

The generic ingredient in OXALIPLATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.

Summary for 205529

Tradename:	OXALIPLATIN
Applicant:	Eugia Pharma
Ingredient:	oxaliplatin
Patents:	0

Pharmacology for NDA: 205529

Suppliers and Packaging for NDA: 205529

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	205529	ANDA	Eugia US LLC	55150-331	55150-331-01	1 VIAL in 1 CARTON (55150-331-01) / 10 mL in 1 VIAL
OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	205529	ANDA	Eugia US LLC	55150-332	55150-332-01	1 VIAL in 1 CARTON (55150-332-01) / 20 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	50MG/10ML (5MG/ML)
Approval Date:	Sep 6, 2017	TE:	AP	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	100MG/20ML (5MG/ML)
Approval Date:	Sep 6, 2017	TE:	AP	RLD:	No

Complete Access Available with Subscription